Cross-linked sodium hyaluronate 23 mg/ml with 0.3% lidocaine hydrochloride - India CDSCO Medical Device Registration

Cross-linked sodium hyaluronate 23 mg/ml with 0.3% lidocaine hydrochloride is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2023/000026_2a2b578e6cde921762824dfdb4d2a54c_975b11a726ffbef0b35c7c46d8ab993a. This device is marketed under the brand name Secondary Packing / Labeling / Stickering / Overprinting / Stamping. The license holder is REENAV LOGISTICS PVT LTD, and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database

CDSCO Registered

Class Class C

Cross-linked sodium hyaluronate 23 mg/ml with 0.3% lidocaine hydrochloride

UID: MFG/MD/2023/000026_2a2b578e6cde921762824dfdb4d2a54c_975b11a726ffbef0b35c7c46d8ab993a

Brand Name

Secondary Packing / Labeling / Stickering / Overprinting / Stamping

License Holder

REENAV LOGISTICS PVT LTD

Device Class

Class C

Approving Authority

Central Drug Standards Control Organization, West Zone

Product Information

The device is indicated to correct moderate to severe nasolabial folds and to increase lip volume. It is indicated to be injected into the mid to deep dermis and submucosa. The intended purpose of the device is to create volume in order to correct wrinkles and folds, to correct moderate to severe nasolabial folds, and to improve lip volume to treat signs of ageing